{"meta":{"totalResults":8,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"CHOP-rituximab"},{"type":"Synonym","name":"rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone regimen"},{"type":"Synonym","name":"R-CHOP"},{"type":"Abbreviation","name":"CTX/DOX/MOAB IDEC-C2B8/PRED/VCR"},{"type":"Synonym","name":"cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine"},{"type":"Synonym","name":"Rituxan/CHOP"},{"type":"Synonym","name":"rituximab/cyclophosphamide/doxorubicin/prednisone/vincristine"}],"definition":{"html":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","text":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenström macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/R-CHOP","text":"R-CHOP"},"nciConceptId":"C9760","nciConceptName":"R-CHOP Regimen","termId":632130,"name":"R-CHOP regimen","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"r-chop-regimen"},{"aliases":[{"type":"Synonym","name":"rituximab-cyclophosphamide-vincristine-prednisone regimen"},{"type":"Synonym","name":"CVP-rituximab"},{"type":"Synonym","name":"CVP/rituximab"},{"type":"Synonym","name":"cyclophosphamide/prednisone/rituximab/vincristine"},{"type":"Synonym","name":"cyclophosphamide/vincristine/prednisone/rituximab"}],"definition":{"html":"A regimen consisting of cyclophosphamide, vincristine, prednisone (CVP) and rituximab that may be used in the treatment of some forms of non-Hodgkin's lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), Castleman disease and post-transplant lymphoproliferative disorders.","text":"A regimen consisting of cyclophosphamide, vincristine, prednisone (CVP) and rituximab that may be used in the treatment of some forms of non-Hodgkin's lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), Castleman disease and post-transplant lymphoproliferative disorders."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/R-CVP","text":"R-CVP"},"nciConceptId":"C63473","nciConceptName":"R-CVP Regimen","termId":710967,"name":"R-CVP regimen","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"r-cvp-regimen"},{"aliases":[{"type":"Synonym","name":"REPOCH regimen"},{"type":"Synonym","name":"rituximab-etoposide-prednisone-Oncovin-cyclophosphamide-hydroxydaunorubicin regimen"},{"type":"Synonym","name":"rituximab/etoposide/prednisone/vincristine/cyclophosphamide/doxorubicin regimen"},{"type":"Synonym","name":"rituximab-EPOCH regimen"}],"definition":{"html":"A regimen consisting of rituximab, followed by a continuous infusion of etoposide, vincristine and doxorubicin, given with prednisone and a bolus dose of cyclophosphamide, used for the treatment of aggressive forms of non-Hodgkin's lymphoma, including mantle cell lymphoma.","text":"A regimen consisting of rituximab, followed by a continuous infusion of etoposide, vincristine and doxorubicin, given with prednisone and a bolus dose of cyclophosphamide, used for the treatment of aggressive forms of non-Hodgkin's lymphoma, including mantle cell lymphoma."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/R-EPOCH","text":"R-EPOCH"},"nciConceptId":"C63461","nciConceptName":"EPOCH-R Regimen","termId":768572,"name":"R-EPOCH regimen","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"epoch-r-regimen"},{"aliases":[{"type":"Synonym","name":"RICE regimen"},{"type":"Synonym","name":"rituximab-ifosfamide-carboplatin-etoposide regimen"},{"type":"Synonym","name":"ICE plus rituximab"},{"type":"Synonym","name":"ifosfamide/carboplatin/etoposide/rituximab"},{"type":"Synonym","name":"rituximab/ifosfamide/carboplatin/etoposide"},{"type":"Synonym","name":"rituximab/ifosfamide/carboplatin/etoposide regimen"}],"definition":{"html":"A regimen consisting of rituximab, ifosfamide, carboplatin and etoposide that can be used for the treatment of nodular lymphocyte-predominant Hodgkin lymphoma and certain forms of non-Hodgkin lymphoma (NHL), such as Burkitt lymphoma and diffuse large B-cell lymphoma.","text":"A regimen consisting of rituximab, ifosfamide, carboplatin and etoposide that can be used for the treatment of nodular lymphocyte-predominant Hodgkin lymphoma and certain forms of non-Hodgkin lymphoma (NHL), such as Burkitt lymphoma and diffuse large B-cell lymphoma."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/R-ICE","text":"R-ICE"},"nciConceptId":"C63465","nciConceptName":"R-ICE Regimen","termId":782307,"name":"R-ICE regimen","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"r-ice-regimen"},{"aliases":[{"type":"Synonym","name":"rituximab-arrx"},{"type":"Synonym","name":"rituximab biosimilar BI 695500"},{"type":"CodeName","name":"ABP 798"},{"type":"CodeName","name":"IDEC-C2B8"},{"type":"CodeName","name":"IDEC-102"},{"type":"CodeName","name":"CT-P10"},{"type":"Synonym","name":"rituximab biosimilar SIBP-02"},{"type":"Synonym","name":"rituximab ARRX"},{"type":"Synonym","name":"rituximab-pvvr"},{"type":"Synonym","name":"chimeric anti-CD20 antibody"},{"type":"Synonym","name":"IDEC-C2B8 monoclonal antibody"},{"type":"Synonym","name":"rituximab biosimilar SAIT101"},{"type":"Synonym","name":"C2B8 monoclonal antibody"},{"type":"Synonym","name":"rituximab PVVR"},{"type":"USBrandName","name":"Truxima"},{"type":"Synonym","name":"rituximab biosimilar RTXM83"},{"type":"USBrandName","name":"Ruxience"},{"type":"CodeName","name":"RTXM83"},{"type":"Synonym","name":"rituximab biosimilar PF-05280586"},{"type":"Synonym","name":"monoclonal antibody IDEC-C2B8"},{"type":"USBrandName","name":"Rituxan"},{"type":"CodeName","name":"BI 695500"},{"type":"USBrandName","name":"Riabni"},{"type":"CodeName","name":"rituximab biosimilar JHL1101"},{"type":"CodeName","name":"PF-05280586"},{"type":"Synonym","name":"rituximab biosimilar IBI301"},{"type":"Synonym","name":"rituximab biosimilar TQB2303"},{"type":"Synonym","name":"rituximab ABBS"},{"type":"Synonym","name":"rituximab biosimilar ABP 798"},{"type":"ForeignBrandName","name":"MabThera"},{"type":"Synonym","name":"rituximab biosimilar GB241"},{"type":"Synonym","name":"rituximab biosimilar CT-P10"},{"type":"Synonym","name":"rituximab-abbs"},{"type":"CASRegistryName","name":"174722-31-7"},{"type":"ForeignBrandName","name":"Ikgdar"},{"type":"ForeignBrandName","name":"Mabtas"}],"definition":{"html":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.","text":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/rituximab","text":"Rituximab"},"nciConceptId":"C1702","nciConceptName":"Rituximab","termId":42613,"name":"rituximab","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"rituximab"},{"aliases":[{"type":"USBrandName","name":"Rituxan Hycela"},{"type":"Synonym","name":"rituximab/hyaluronidase human"},{"type":"Synonym","name":"rituximab plus hyaluronidase"},{"type":"Synonym","name":"rituximab/hyaluronidase"}],"definition":{"html":"A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC). When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs. CD20 is expressed on the surface of pre-B and mature Blymphocytes, and is overexpressed in a variety of B-cell malignancies.\n","text":"A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC). When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs. CD20 is expressed on the surface of pre-B and mature Blymphocytes, and is overexpressed in a variety of B-cell malignancies.\n"},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/rituximabandhyaluronidasehuman","text":"Rituximab and Hyaluronidase Human"},"nciConceptId":"C136821","nciConceptName":"Rituximab and Hyaluronidase Human","termId":789585,"name":"rituximab and hyaluronidase human","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"rituximab-and-hyaluronidase-human"},{"aliases":[{"type":"CodeName","name":"CON-4619"},{"type":"USBrandName","name":"Aurixim"},{"type":"Synonym","name":"aurixim antibody conjugate"}],"definition":{"html":"A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.","text":"A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells."},"drugInfoSummaryLink":null,"nciConceptId":"C148162","nciConceptName":"Rituximab Conjugate CON-4619","termId":792533,"name":"rituximab conjugate CON-4619","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"rituximab-conjugate-con-4619"},{"aliases":[{"type":"Synonym","name":"rituximab/ifosfamide/cytarabine/etoposide"},{"type":"Synonym","name":"rituximab-ifosfamide-cytarabine-etoposide"},{"type":"Synonym","name":"rituximab + ifosfamide + cytarabine + etoposide"},{"type":"Synonym","name":"R-IVAC regimen"},{"type":"Synonym","name":"rituximab/ifosphamide/VP-16/ARA-C"},{"type":"Abbreviation","name":"RIVAC"},{"type":"Abbreviation","name":"R-IVAC"}],"definition":{"html":"A regimen consisting of rituximab, ifosfamide, cytarabine and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL).","text":"A regimen consisting of rituximab, ifosfamide, cytarabine and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL)."},"drugInfoSummaryLink":null,"nciConceptId":"C153313","nciConceptName":"RIVAC Regimen","termId":794075,"name":"RIVAC regimen","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"rivac-regimen"}],"links":null}